- Previous Close
3.4700 - Open
3.4150 - Bid 3.4850 x --
- Ask 3.6600 x --
- Day's Range
3.4150 - 3.5800 - 52 Week Range
3.0600 - 5.8152 - Volume
5,184 - Avg. Volume
4,025 - Market Cap (intraday)
190.633M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6700 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
www.genfit.comRecent News: 0QT6.IL
View MorePerformance Overview: 0QT6.IL
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0QT6.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0QT6.IL
View MoreValuation Measures
Market Cap
176.17M
Enterprise Value
182.33M
Trailing P/E
9.66
Forward P/E
7.53
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.58
Price/Book (mrq)
1.83
Enterprise Value/Revenue
2.40
Enterprise Value/EBITDA
6.37
Financial Highlights
Profitability and Income Statement
Profit Margin
-116.97%
Return on Assets (ttm)
-9.59%
Return on Equity (ttm)
-37.21%
Revenue (ttm)
29.22M
Net Income Avi to Common (ttm)
-34.17M
Diluted EPS (ttm)
-0.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
111.83M
Total Debt/Equity (mrq)
101.21%
Levered Free Cash Flow (ttm)
-26.86M